CRSP

CRISPR Therapeutics AG

Halal Rating :
Comfortable
Last Price $40.70 Last updated:
Market Cap $4.06b
7D Change 4.76%
1 Year Change -37.63%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 4, 2024

CRISPR Therapeutics AG is a gene editing company focused on developing transformative gene-based medicines for serious diseases. The company's primary focus is on developing treatments using its CRISPR/Cas9 gene-editing platform, which enables precise, directed changes to genomic DNA. Their lead product, exa-cel (formerly known as CTX001), is being developed for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $602000.0 $110.73m - - 0.00% 0.00%
June 30, 2024 $517000.0 $151.78m - - 0.00% 0.00%
March 31, 2024 $504000.0 $141.09m - - 0.00% 0.00%

Company Impact

Help us evaluate CRISPR Therapeutics AG's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates